Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a biopharmaceutical company dedicated to developing innovative therapies for cardiovascular and renal diseases. The company is focused on addressing unmet medical needs through its advanced research and development efforts. Competing within the pharmaceutical sector, Mineralys aims to bring effective treatments to the market, challenging other companies in the same space.
On March 13, 2026, Dennis Ding from Jefferies set a price target of $30 for MLYS. At that time, the stock was trading at $26.23, suggesting a potential upside of approximately 14.37%. This optimistic outlook reflects confidence in the company's future performance and growth potential, as highlighted by StreetInsider.
Recently, MLYS held its Q4 2025 earnings call, providing insights into its financial performance and strategic initiatives. The call highlighted significant developments and plans for growth, offering valuable information for investors and stakeholders interested in the company's trajectory.
Currently, MLYS is priced at $26.19, reflecting a decrease of 2.96% with a drop of $0.80. The stock has fluctuated between a low of $25.45 and a high of $28.65 during the day. Over the past year, MLYS has reached a high of $47.65 and a low of $10.44, indicating significant volatility.
The company's market capitalization stands at approximately $1.74 billion, reflecting its size and market presence. Today's trading volume for MLYS on the NASDAQ is 1,380,806 shares, indicating active investor interest and engagement with the stock.
